Prostate-specific membrane antigen (PSMA) is overexpressed in most cases of prostate cancer and is potentially associated with metastasis and progression of prostate cancer. Compared with 68Ga, the PET radionuclide 18F exhibits several advantages. 18F-Thretide (18F-labeled PSMA ligand) has been studied for preclinical evaluation and Pilot Clinical Study. This study evaluates the diagnostic performance and safety of 18F-Thretide PET/CT in patients with suspected recurrence of prostate cancer who have negative or equivocal findings on conventional imaging.
This study evaluates the diagnostic performance and safety of 18F-Thretide PET/CT in patients with suspected recurrence of prostate cancer who have negative or equivocal findings on conventional imaging.